{
    "2020-02-11": [
        [
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst Blog",
                        "Microsoft",
                        "JP Morgan Chase",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "finance",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Pfizer Stock Tumbled On Its Earnings Report — Should You Add Shares?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock Tumbled",
                        "Earnings Report"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC",
                "features": {
                    "keywords": [
                        "XTANDI",
                        "enzalutamide",
                        "Significant Improvement",
                        "Overall Survival",
                        "Phase 3",
                        "PROSPER Trial",
                        "nmCRPC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",
                "features": {
                    "keywords": [
                        "Daily Biotech Pulse",
                        "LogicBio",
                        "Clinical Hold",
                        "Agile",
                        "Debt Deal",
                        "Twirla Approval",
                        "Gilead",
                        "Sierra Oncology"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}